Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELZNASDAQ:CURNASDAQ:FRTXNASDAQ:TTNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELZCreative Medical Technology$2.02+3.1%$2.11$1.69▼$6.90$5.22M250,185 shs19,502 shsCURNeuralstem$0.81+6.7%$1.06$1.10▼$13.78$1.70M1.81236,278 shs91,573 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsTTNPTitan Pharmaceuticals$4.43-3.6%$3.98$3.03▼$14.80$4.04M1.25138,918 shs21,131 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELZCreative Medical Technology+3.06%0.00%+2.54%-62.59%-53.24%CURNeuralstem-0.59%+11.23%+9.81%-19.79%-86.02%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%+2.75%+3.89%TTNPTitan Pharmaceuticals-3.59%-5.25%+21.73%+20.57%-33.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELZCreative Medical TechnologyN/AN/AN/AN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATTNPTitan Pharmaceuticals0.1882 of 5 stars0.03.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELZCreative Medical Technology 0.00N/AN/AN/ACURNeuralstem 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ATTNPTitan Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELZCreative Medical Technology$14K373.12N/AN/A$7.48 per share0.27CURNeuralstem$260K6.52N/AN/A$6.64 per share0.12FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56TTNPTitan Pharmaceuticals$180K22.47N/AN/A$8.82 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELZCreative Medical Technology-$5.29M-$3.81N/AN/AN/AN/A-63.05%-60.42%8/8/2025 (Estimated)CURNeuralstem-$4.93MN/A0.00∞N/A-39,417.64%-170.51%-110.16%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ATTNPTitan Pharmaceuticals-$5.57M-$4.59N/A∞N/AN/A-118.01%-103.79%N/ALatest CUR, FRTX, CELZ, and TTNP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TTNPTitan PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/9/2025Q1 2025CELZCreative Medical Technology-$0.52-$0.83-$0.31-$0.83N/A$0.00 million3/20/2025Q4 2024TTNPTitan PharmaceuticalsN/A-$0.85N/A-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELZCreative Medical TechnologyN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELZCreative Medical TechnologyN/A19.1319.12CURNeuralstemN/A2.532.53FRTXFresh Tracks TherapeuticsN/AN/AN/ATTNPTitan PharmaceuticalsN/A9.719.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELZCreative Medical Technology1.42%CURNeuralstem38.30%FRTXFresh Tracks Therapeutics25.04%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipCELZCreative Medical Technology2.80%CURNeuralstem5.38%FRTXFresh Tracks Therapeutics0.23%TTNPTitan Pharmaceuticals0.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELZCreative Medical Technology52.59 million1.70 millionNot OptionableCURNeuralstem62.10 millionN/ANot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableTTNPTitan Pharmaceuticals10914,000686,000OptionableCUR, FRTX, CELZ, and TTNP HeadlinesRecent News About These CompaniesTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockApril 11, 2025 | globenewswire.comTitan Pharmaceuticals: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comTitan Pharmaceuticals receives Nasdaq notice of non-complianceNovember 27, 2024 | markets.businessinsider.comTitan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee RequirementsNovember 27, 2024 | quiverquant.comTitan Pharmaceuticals, Inc. Announces Receipt of Notice from NasdaqNovember 27, 2024 | globenewswire.comSanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatOctober 25, 2024 | msn.comTitan Pharmaceuticals, Inc. (TTNP)October 17, 2024 | finance.yahoo.com(TTNP) Technical Pivots with Risk ControlsSeptember 25, 2024 | news.stocktradersdaily.comWhen (TTNP) Moves Investors should ListenSeptember 15, 2024 | news.stocktradersdaily.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, FRZA, TTNP on Behalf of ShareholdersSeptember 9, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, CFB, TTNP, DFS on Behalf of ShareholdersSeptember 5, 2024 | stockhouse.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNPSeptember 5, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNPSeptember 4, 2024 | prnewswire.comTitan Pharmaceuticals Share Price (TTNP.US)August 24, 2024 | lse.co.ukShareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public ShareholdersAugust 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Titan Pharmaceuticals, Inc. MergerAugust 22, 2024 | markets.businessinsider.comCrude Oil Falls; Palo Alto Networks Shares Jump After Q4 EarningsAugust 21, 2024 | msn.comTitan Pharma enters into merger agreement with KE Sdn. Bhd.August 21, 2024 | pharmabiz.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of ShareholdersAugust 20, 2024 | stockhouse.comTitan Pharmaceuticals Shares Double on Reverse Merger DealAugust 20, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Cybersecurity Stocks Are Defying the DownturnBy Ryan Hasson | April 29, 2025View These 3 Cybersecurity Stocks Are Defying the Downturn3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBy Nathan Reiff | May 16, 2025View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioAmazon: Why The Great Comeback Rally Could Be About to BeginBy Sam Quirke | May 5, 2025View Amazon: Why The Great Comeback Rally Could Be About to BeginTaiwan Semiconductor Has a New Reason to Rally on Chip CurbsBy Gabriel Osorio-Mazilli | May 9, 2025View Taiwan Semiconductor Has a New Reason to Rally on Chip CurbsCUR, FRTX, CELZ, and TTNP Company DescriptionsCreative Medical Technology NASDAQ:CELZ$2.02 +0.06 (+3.06%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$2.02 0.00 (0.00%) As of 05/23/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Titan Pharmaceuticals NASDAQ:TTNP$4.42 -0.17 (-3.59%) Closing price 05/23/2025 03:57 PM EasternExtended Trading$4.54 +0.12 (+2.71%) As of 05/23/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
